HDAC3 inhibition as a therapeutic strategy in T-cell acute lymphoblastic leukemia via the TYK2-STAT1-BCL2 signaling pathway
Our results highlight the effectiveness of the combination of chidamide and chemotherapy in the treatment of T-ALL patients and suggest that HDAC3 can act as a potential novel therapeutic target to inhibit the TYK2-STAT1-BCL2 signaling pathway in T-ALL.
Authors
- Yan Xu (ORCID: https://orcid.org/0000-0003-0379-8866)
- Ning Le (ORCID: https://orcid.org/0000-0002-9267-690X)
- Hao Wang (ORCID: https://orcid.org/0000-0001-6881-9977)
- Liping Dou (ORCID: https://orcid.org/0000-0001-7352-9560)
- Daihong Liu
- Chunji Gao
- Xiawei Zhang
- Zhenyang Gu
- Yuchen Liu
- Lili Wang
- Qingyang Liu
Institutions
- Chinese PLA General Hospital (CN)
- Chinese General Hospital College of Nursing and Liberal Arts (PH)
- Soochow University (CN)
- National Clinical Research (US)
- First Affiliated Hospital of Soochow University (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2026-02-04
- DOI
- https://doi.org/10.3389/fimmu.2026.1752727
- Primary Topic
- Histone Deacetylase Inhibitors Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00